What Researchers Did
Researchers investigated if hyperbaric oxygen (HBO) enhanced the effectiveness of cisplatin chemotherapy in treating epithelial ovarian cancer using xenograft models in nu/nu mice.
What They Found
HBO exposure led to dramatic tumor neovascularization (P = 0.0001) and, in Phase I, significant tumor growth retardation (P = 0.014) when combined with cisplatin compared to cisplatin alone. This significant retardation was observed after two cisplatin doses but was not sustained due to reduced mouse numbers.
What This Means for Canadian Patients
While this study was conducted in mice, the findings suggest that hyperbaric oxygen might enhance the effectiveness of chemotherapy for ovarian cancer. Further research, including human trials, would be necessary to determine if this approach could benefit Canadian patients with chemotherapy-resistant ovarian cancer.
Canadian Relevance
This study has no direct Canadian connection, as it was not conducted in Canada nor involved Canadian researchers or patients.
Study Limitations
A key limitation is that this was a preclinical study in mice, and the observed significance in tumor growth retardation was not sustained due to reduced animal numbers.